Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
Health Technology » Pharmaceuticals Major
|MRK||Merck & Co., Inc.||0.75%||82.27||0.7%||$1554.99m|
|JNJ||Johnson & Johnson||1.03%||165.77||0.7%||$1044.61m|
|LLY||Eli Lilly & Co.||1.40%||248.48||1.1%||$639.12m|
|BMY||Bristol-Myers Squibb Co.||0.69%||58.21||1.0%||$634.93m|
|AVIR||Atea Pharmaceuticals, Inc.||-2.59%||12.39||0.3%||$123.47m|
|NVO||Novo Nordisk A/S||1.14%||107.38||0.1%||$90.85m|
|OGN||Organon & Co.||-0.46%||36.74||0.0%||$53.17m|
Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of targeted therapies for women's cancers. The company also focuses on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.